Assessing patient participation in lung and esophageal cancer treatment
A Prospective Observational Study on the Level of Patient Participation in Lung and Esophageal Cancer Patients Treated With Definitive Radiochemotherapy.
This study looks at how involved lung and esophageal cancer patients are in their treatment to see if their participation affects side effects, quality of life, and survival rates.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Sun Yat-sen University Academic / other |
| Drugs / interventions | immunotherapy, chemotherapy |
| Locations | 1 site (Guangzhou) |
| Trial ID | NCT06019455 on ClinicalTrials.gov |
What this trial studies
This observational study evaluates how actively lung and esophageal cancer patients engage in their treatment processes while receiving definitive radiotherapy and chemotherapy, with or without immunotherapy. It aims to explore the relationship between patient participation levels and outcomes such as side effects, quality of life, and long-term survival. The study will gather perspectives from both patients and medical staff to compare their views on participation and its impact on treatment results.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 to 75 with locally advanced non-small cell lung cancer, limited-stage small cell lung cancer, or esophageal cancer who are set to undergo definitive chemoradiotherapy.
Not a fit: Patients with cognitive impairments may not benefit from this study due to challenges in communication and participation.
Why it matters
Potential benefit: If successful, this study could enhance patient involvement in their treatment, potentially leading to improved outcomes and quality of life.
How similar studies have performed: While the specific approach of assessing patient participation in this context may be novel, similar studies have shown that increased patient engagement can positively influence treatment outcomes.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Locally advanced non-small cell lung cancer, limited-stage small cell lung cancer, and esophageal cancer. * Planned to undergo definitive chemoradiotherapy ± immunotherapy; * Males or females aged 18 to 75; * Able to communicate with medical staff. Exclusion Criteria: Patients with cognitive impairments.
Where this trial is running
Guangzhou
- Sun Yat-sen University — Guangzhou, China (Recruiting)
Study contacts
- Study coordinator: Bo Qiu
- Email: qiubo@sysucc.org.cn
- Phone: +862087343031
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.